European Union - Slovenian - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - irbesartan - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije. zdravljenje ledvične bolezni pri bolnikih s hipertenzijo in tip 2 sladkorna bolezen kot del antihypertensive zdravila režim (glej poglavje 5.

European Union - Slovenian - EMA (European Medicines Agency)

lipomed gmbh - cladribine - leukemija, dlakasta celica - antineoplastična sredstva - litak je indiciran za zdravljenje leukemije dlakavice.

European Union - Slovenian - EMA (European Medicines Agency)

orexigen therapeutics ireland limited - bupropion hidroklorid, naltrekson hidroklorid - obesity; overweight - preparati za zaščito proti sončenju, prehrambeni izdelki - mysimba je označena, kot dodatek k zmanjšano kalorično prehrano in večjo telesno dejavnost, za upravljanje teža v odrasli bolniki (≥18 let) z začetnim indeksom telesne mase (bmi)≥ 30 kg/m2 (debelih), ali≥ 27 kg/m2 < 30 kg/m2 (prekomerno telesno težo) v prisotnosti enega ali več teže, povezanih s co morbidities (e. tip 2 sladkorne bolezni, dyslipidaemia, ali pod nadzorom hipertenzija), zdravljenje z mysimba je treba prekiniti po 16 tednih, če bolniki niso izgubili vsaj 5% njihove začetne telesne teže.

European Union - Slovenian - EMA (European Medicines Agency)

ge healthcare as  - regadenoson - myokardno perfuzijsko slikanje - srčna terapija - to zdravilo je samo za diagnostično uporabo. rapiscan je selektivno koronarnih vazodilatator za uporabo kot farmakološke stres agent za radionuklid miokardni perfuzijo imaging (mpi) pri odraslih bolnikih, ne more opraviti ustrezno uresničevanje stres.

European Union - Slovenian - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

European Union - Slovenian - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetat - diagnostične tehnike, endokrine - macimorelin - to zdravilo je samo za diagnostično uporabo.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

European Union - Slovenian - EMA (European Medicines Agency)

theramex ireland limited - teriparatid - osteoporoza - kalcij homeostaza - livogiva is indicated in adults. zdravljenje osteoporoze pri ženskah po menopavzi in pri moških z večjim tveganjem zloma. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. zdravljenje osteoporoze, povezane s trajno sistemsko glukokortikoidnih terapija pri ženskah in moških na povečano tveganje za zlom.

European Union - Slovenian - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatid - osteoporoza - kalcij homeostaza - sondelbay is indicated in adults. zdravljenje osteoporoze pri ženskah po menopavzi in pri moških z večjim tveganjem zloma. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. zdravljenje osteoporoze, povezane s trajno sistemsko glukokortikoidnih terapija pri ženskah in moških na povečano tveganje za zlom.

European Union - Slovenian - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

European Union - Slovenian - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.